IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Examiner: To be Assigned
Avi J. ASHKENAZI, et al.)) Art Unit: To be Assigned
Application Serial No. To be Assigned) Parent Serial No. 09/918,585
Filed: Herewith) Parent Filed: July 30, 2001
For: SECRETED AND TRANSMEMBRANE) Attorney's Docket No. 39780-2630 P1C1C1
POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME	,) Customer No. 35489)

EXPRESS MAIL LABEL NO. <u>EL 977 676 945 US</u>

Date Mailed: MARCH 18, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Mail Stop Patent Application Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If Form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

⊠ apply):	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that						
	\boxtimes	(1)	It is being filed within 3 month than a continued prosecution OR	s of the application filing date and is other application under § 1.53(d)			
		(2)	It is being filed within 3 month	s of entry of a national stage			
		(3)		I date of the first Office Action on the merits			
		(4)		ling of a first Office Action after the filing of a ation under § 1.114.			
	37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:						
		a certif	fication as specified in §1.97(e) is provided below; or			
				(p) is authorized below, enclosed, or apers filed together with this statement.			
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:						
	A.	a certif	fication as specified in §1.97(e) is completed below; and			
	 B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this standard submitted herewith; and. 						
	C.		a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or ncluded with the payment of other papers filed together with this statement.				
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39780-2630 P1C1C1.</u>						
				Respectfully submitted,			
Dated: March 18, 2004		04	By: Ginger R. Dreger (Reg. No. 33,055)				
275 Mi Menlo Teleph	ddlefiel Park, C one: (6	d Road	a 94025-3506 4-7000	3 (

2

Form PTO-1449 Attorney's Docket No. Application Serial No. 39780-2630 P1C1C1 To be Assigned Applicant(s) INFORMATION DISCLOSURE STATEMENT Avi J. ASHKENAZI, et al. Filing Date: **Group Art Unit:** (use several sheets if necessary) Herewith To be Assigned U.S. PATENT DOCUMENTS Ref. Examiner Date Document No. Name Class Subclass **Filing Date** Initials No. (if appropriate) 1.* 10/99 5,968,744 Hillman, et al. 435 6 FOREIGN PATENT DOCUMENTS Sep. 80 a Examiner Ref. Date Document No. Name Class Subclass **Translation** Initials No. YES NO 2.* 3/99 WO 99/10363 PCT C017h 21/00 3.* 7/99 WO 99/33979 PCT C12N 15/00 4.* 9/99 WO 99/43802 PCT C12N 15/12 10/99 WO 99/50405 PCT C12N 15/12 OTHER DOCUMENTS 17.5 (including author, title, date, pertinent pages, etc.) Examiner Ref. Title Initials No. 6. Kato, S. et al., "New proteins and DNA useful for preventing tumours", Accession No. P_AAZ11186, WO 9943802-A2, filed 2/25/99, pub. 9/2/99 Fan, P. et al., "New isolated human genes and the secreted polypeptides they encode useful for diagnosis and 7. treatment of e.g. cancers, neurological disorders, immune diseases, inflammation or blood disorders", Accession No. P_AAX30168, WO9910363, filed 8/27/98, pub. 3/4/99 8. NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap., "National Cancer Institute, Cancer Genome Anatomy Project (CGAP). Tumor Gene Index", Accession No. AA902726, unpublished 9. NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap., "National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index", Accession No. AA689524, unpublished 10. Jacobs, K. et al., "Polynucleotides encoding secreted human proteins, derived from human adult brain, human fetal brain, human fetal kidney, and human adult blood cDNA libraries", Accession No. P AAX90853, WO9950405-A1, filed 3/30/99, pub. 10/7/99 11. GenPept AAD32301; Oct. 24, 1997 12. EMBL AF031379; Oct. 24, 1997 13. Hwang, et al., "The Mouse Cornichon Gene Family", Dev. Genes Evol., - 209:120-125 (1999) 14. Carninci and Hayashizaki, "High-Efficiency Full-Length cDNA cloning", Meth. Enzymol., - 303:19-44 (1999) 15. Roth, et al., Cell - 81:967-978 (1995) 16. Blast Results A1-A13 (Alignment of DNA233330 and various nucleotide sequences - GenBank Database), Oct. 4, 2001 17. Blast Results B1-B4 (Alignment of DNA23330 and various polypeptides sequences - Dayhoff Database), Oct. 3, 2001 18. Skolnick, et al., Trends in Biotech - 18(1):34-39 (2000) 19. Jobling, et al., Mol. Microbiol., 5(7):1755-1767 (1991)

EXAMINER:	 	DATE CONSIDERED:
E/O BITTLE IV.		DATE CONSIDERED.

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). SV 2013136 v1